European Commission Directorate-General for International Partnerships (EuropeAid HQ)

Paragon Novel Vaccine (PNV) an effective protection against all serotypes of five deadly bacteria to eradicate Antimicrobial Resistance (AMR): PARAGON NOVEL VACCINE

Last update: Mar 28, 2023 Last update: Mar 28, 2023

Details

Locations:Portugal
Start Date:Jan 1, 2023
End Date:Jun 30, 2025
Contract value:EUR 7,400,192
Sectors:Health, Science & InnovationHealth, Science & Innovation
Categories:Grants
Date posted:Mar 28, 2023

Associated funding

Associated experts

Description

Programme(s): HORIZON.3.1 - The European Innovation Council (EIC)

Topic(s): HORIZON-EIC-2022-ACCELERATOROPEN-01 - EIC Accelerator Open

Call for proposal: HORIZON-EIC-2022-ACCELERATOR-01

Funding Scheme: EIC-ACC - EIC-ACC

Grant agreement ID: 190152193

Objective:
Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine). It protects against bacterial infections caused by 5 different bacteria: S. aureus, S. pneumoniae, K. pneumoniae, E. coli and GBS. Our innovation relies on the discovery of a virulence and immunosuppressive mechanism common to these pathogens. The bacteria excrete a highly immunosuppressive protein designated as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which disables the host immune response to infection. PNV works by blocking bacterial GAPDH, while not reacting to human GAPDH, allowing the host immune system to fight infection and eliminate the bacteria. Preclinical trials demonstrated high levels of efficacy against any of the 5 bacteria with an excellent safety profile. PNV is the world’s first vaccine not only to prevent multiple bacterial infections but for all invasive serotypes, including multi-resistant strains.

 

Want to unlock full information?
Member-only information. Become a member to access projects awards, find the right consortia partners, subcontractors and more.